Pramlintide

Human amylin aggregates into amyloid fibrils, so pramlintide substitutes proline at positions 25, 28 and 29 (borrowing from the non-amyloidogenic rat sequence) to make a soluble, injectable analogue. It acts on amylin receptors in the area postrema to do three things insulin cannot: slow gastric emptying, suppress the inappropriate postprandial glucagon rise seen in diabetes, and promote satiation. In type 1 and insulin-treated type 2 diabetes this flattens the postprandial glucose curve and typically produces 1-2 kg of weight loss. The catch is that slowing gastric emptying while injecting mealtime insulin is a recipe for severe hypoglycaemia if insulin doses are not cut.

Targets: Amylin receptors (AMY1-3), Calcitonin receptor

• · Start at 15 mcg and increase in 15 mcg steps to 30, 45 then 60 mcg as nausea allows. Mealtime insulin must be cut by 50% when starting.
• · Start at 60 mcg and increase to 120 mcg after 3-7 days if nausea has settled. Mealtime insulin cut by 50% at initiation.

Work out your exact syringe units →

• very commonNausea— Affects around 30-50% of users; usually settles over 4 weeks.
• commonSevere insulin-induced hypoglycaemia— Boxed warning. Occurs within three hours of injection, typically in the first four weeks. This is the reason mealtime insulin must be halved at initiation.
• commonAnorexia and vomiting
• commonHeadache
• commonInjection-site reaction

• Confirmed gastroparesis - pramlintide makes it substantially worse.
• Hypoglycaemia unawareness.
• Poor compliance with glucose monitoring or with insulin dose adjustment.
• HbA1c above 9% with recurrent severe hypoglycaemia.
• Concomitant drugs that stimulate gastrointestinal motility.

• cautioninsulin-analogues — The central interaction - halve mealtime insulin at initiation and monitor closely. Never mix in the same syringe.
• redundantcagrilintide — Both are amylin analogues; cagrilintide is the weekly version.
• cautionsemaglutide — Both slow gastric emptying; the combination amplifies gastroparesis-like symptoms and oral drug absorption delays.

• · Pre- and post-meal glucose, and at bedtime, especially in the first month.
• · Insulin dose adjustments in writing.
• · Weight.
• · Nausea severity as the titration guide.

FDA-approved as Symlin for use with mealtime insulin. Not approved in the EU.

• Symlin US prescribing information, including boxed warning for severe hypoglycaemia (label)
• Hollander et al. 2003, pramlintide in type 2 diabetes, Diabetes Care (trial)
• Ratner et al. 2004, pramlintide in type 1 diabetes, Diabetic Medicine (trial)

Pramlintide exists because of a formulation problem, not a pharmacology problem. Native human amylin is a perfectly good drug candidate that cannot be made into a product, because it self-assembles into amyloid fibrils - the same islet amyloid deposits found in the pancreas in type 2 diabetes. Substituting three prolines from the rat sequence, which does not form amyloid, gives a soluble analogue with intact receptor activity. That is pramlintide. Physiologically it replaces something that is genuinely missing: amylin is co-secreted with insulin, so anyone with type 1 diabetes or advanced beta-cell failure is amylin-deficient as well as insulin-deficient, and injecting insulin alone corrects half of a two-hormone system. The three effects that matter are slowed gastric emptying, suppression of inappropriate postprandial glucagon, and centrally mediated satiation through the area postrema. In practice the glucagon suppression is the underrated one - people with type 1 diabetes secrete glucagon after meals when they should not, and that contributes substantially to postprandial hyperglycaemia that mealtime insulin alone cannot fix without causing later hypoglycaemia. The boxed hypoglycaemia warning is a direct consequence of the mechanism: pramlintide does not cause hypoglycaemia itself, but it delays carbohydrate absorption while the injected mealtime insulin arrives on its own schedule, so if you do not cut the prandial insulin by half at initiation you will go low. The weight effect - typically 1-2 kg, up to about 3-4 kg in the year-long obesity study - is real but modest, and pramlintide's main historical value is as proof that amylin agonism reduces food intake in humans, which is what made cagrilintide, petrelintide and eloralintide worth building.

The failure mode is severe hypoglycaemia within the first two weeks in someone who did not cut their mealtime insulin. The label says halve it; people do not, because halving insulin feels like undertreating, and then the delayed carbohydrate absorption meets a full insulin dose and they end up unconscious. The second problem is that nausea at initiation is common and pushing the dose up on schedule rather than on tolerance guarantees it. The third is practical: three extra injections a day, separate from the insulin injections, in a population already injecting four times daily. That is why uptake was always low despite the drug working.

1. 15 mcgType 1 diabetes, days 1-3 — Immediately before major meals. Halve the mealtime insulin at the same time - this is not optional.
2. 30 mcgType 1 diabetes, next step — Increase only after at least three days without significant nausea.
3. 45 mcgType 1 diabetes, next step
4. 60 mcgType 1 diabetes, target — Maximum mealtime dose in type 1 diabetes.
5. 60 mcgType 2 diabetes, days 1-3 — Type 2 starts higher because insulin sensitivity and the hypoglycaemia risk profile differ.
6. 120 mcgType 2 diabetes, target — Maximum mealtime dose in type 2 diabetes, after at least three days of tolerance at 60 mcg.

• Amylin receptors (AMY1R, AMY2R, AMY3R - calcitonin receptor plus RAMP1/2/3) — Full agonist at the amylin receptor complexes; specific affinities were not verified in this session

  Slowed gastric emptying, suppression of postprandial glucagon, and area postrema satiation.

• Calcitonin receptor (CTR) — Lower activity than at the RAMP-complexed amylin receptors

  Minor at prandial doses and short exposure; less of a concern than with long-acting amylin analogues.

• Pramlintide 12-month obesity trial Phase 2 · n=411 · 52 weeks · 2008

  Sustained weight loss over 12 months as an adjunct to lifestyle intervention in obesity without diabetes.

Tmax at about 20 minutes, effect on the meal it precedes. Half-life 48 minutes, so it is gone before the next meal. No accumulation, no steady state, no washout period - stopping is immediate.

Pramlintide is licensed for use with mealtime insulin and that is where it belongs. The critical operational detail is that it must be injected separately from insulin - the formulations are incompatible and mixing them in one syringe destroys the pramlintide. Use a different injection site at least two inches away. Combining pramlintide with a GLP-1 agonist is mechanistically the same idea as CagriSema, done badly: both delay gastric emptying, both cause nausea, and the pramlintide dosing schedule (three times daily) does not match a weekly agent. If you want amylin plus incretin, the long-acting amylin analogues exist for that reason. There is old interest in pramlintide plus metreleptin for weight, which produced striking results in a phase 2 study and was abandoned; that combination is not obtainable.

Against cagrilintide: the same receptor family with a 48-minute half-life instead of eight days, which is the entire practical difference. Pramlintide is what amylin agonism looks like before anyone solved the duration problem. Against petrelintide and eloralintide: those are selective long-acting amylin agonists with far better tolerability and double-digit weight loss in phase 2. Against a GLP-1 agonist for weight: not close - 1-4 kg versus 15-20%. What pramlintide still uniquely offers is prandial glucagon suppression in type 1 diabetes, which no GLP-1 agonist and no long-acting amylin analogue is licensed to do.

$400–$900/month. US pricing for SymlinPen without coverage. Market observation, not verified pricing.

• ?Volume of distribution and clearance are not reported in the SymlinPen label and were left null.
• ?The stated 60% protein binding is derived from the label's statement that approximately 40% of drug is unbound, rather than a directly reported binding percentage.
• ?The sequence given is the standard published pramlintide sequence with the three proline substitutions; it was not verified residue-by-residue against a structural source.
• ?Specific receptor affinities across AMY1R, AMY2R and AMY3R were not verified.
• ?The 411-participant figure for the 12-month obesity trial was not individually re-verified against the paper.
• ?Cost figures are market observations, not verified pricing.

• Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity Smith SR et al., Diabetes Care, 2008 · PMID 18753666

  The longest pramlintide weight study, and the proof-of-concept that amylin agonism produces durable weight loss in humans - the intellectual foundation for cagrilintide and its successors.

• SYMLINPEN (pramlintide acetate) injection - US prescribing information, section 12.3 AstraZeneca Pharmaceuticals LP, DailyMed

  Source for the 30-40% bioavailability, 19-21 minute tmax, 48-minute half-life, roughly 60% protein binding and the des-lys1 active metabolite.